Stay updated with breaking news from Talat Imran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
06.05.2024 - - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for ...
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Equities researchers at Wedbush decreased their FY2027 earnings per share (EPS) estimates for Rani Therapeutics in a research note issued to investors on Tuesday, February 6th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($1.78) per share for the year, down […]
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) CEO Talat Imran acquired 5,000 shares of the stock in a transaction on Monday, December 4th. The stock was purchased at an average cost of $2.57 per share, with a total value of $12,850.00. Following the transaction, the chief executive officer now directly owns 474,455 shares […]
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) CEO Talat Imran purchased 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $2.05 per share, for a total transaction of $41,000.00. Following the acquisition, the chief executive officer now directly […]